Ipamorelin Dosing in Hepatic Impairment: What Women Need to Know

What Is Ipamorelin and How Does It Work?

Ipamorelin is a synthetic pentapeptide that selectively binds the ghrelin receptor (GHSR-1a) in the pituitary, triggering a sharp, short pulse of growth hormone (GH) release. It does not meaningfully raise cortisol or prolactin at standard doses, which is what separates it from older GHRPs like GHRP-6. Your own pituitary ultimately controls the amplitude of the response, so the drug works with your hypothalamic-pituitary axis rather than bypassing it.

In the United States, ipamorelin is available only through 503A compounding pharmacies and is not FDA-approved as a finished drug product. That regulatory status matters clinically: there is no package insert with a dedicated renal or hepatic-impairment dosing section.

The Ghrelin Receptor Pathway

GH secretagogues bind GHSR-1a on somatotroph cells in the anterior pituitary. Receptor activation opens voltage-gated calcium channels, which drives GH exocytosis. Ipamorelin also amplifies the effect of endogenous growth hormone-releasing hormone (GHRH), so the two signals add together. The resulting GH pulse mirrors a physiological nocturnal peak, which is why most protocols time at least one injection near bedtime.

What the Raun 1998 Trial Established

The foundational selectivity data come from Raun et al. (Eur J Endocrinol, 1998), a rat-model study showing that ipamorelin produced GH release comparable to GHRP-6 without statistically significant rises in ACTH, cortisol, or prolactin. That selectivity profile is why ipamorelin became the preferred research GHRP for populations where cortisol elevation is a concern, including women with PCOS and perimenopausal women who already have dysregulated HPA-axis activity. The study was not conducted in humans, and no large randomized controlled trial in women exists.

The table below summarizes the selectivity comparison that Raun established and that clinicians now use when choosing between GHRPs.

| Peptide | GH Release | Cortisol Rise | Prolactin Rise | |---|---|---|---| | GHRP-6 | High | Moderate | Moderate | | GHRP-2 | High | High | High | | Ipamorelin | High | Minimal | Minimal | | Sermorelin (GHRH) | Moderate | None | None |

How the Liver Processes Ipamorelin

Ipamorelin is a 29-amino-acid pentapeptide cleared primarily by proteolytic degradation in plasma and peripheral tissues, with hepatic metabolism playing a secondary but meaningful role. The liver contributes to peptide hydrolysis and, more importantly, is the primary site of IGF-1 synthesis. That second point is the one most often overlooked in clinical practice.

The IGF-1 Problem in Liver Disease

When you give ipamorelin to a woman with healthy liver function, rising GH drives hepatic IGF-1 production. IGF-1 feeds back on the pituitary to limit further GH release, acting as a natural brake. In significant hepatic impairment, the liver cannot produce adequate IGF-1 even when GH is elevated. The brake fails. GH rises without the normal negative feedback, and you can see GH excess symptoms, including fluid retention, joint pain, paresthesia, and in severe cases, features resembling acromegaly, even at doses that would be completely safe in a woman with normal liver function.

This GH-resistance state is well described in cirrhosis. Møller and Jørgensen (Endocr Rev, 2009) documented elevated basal GH with low IGF-1 in cirrhotic patients, a pattern directly relevant to any GH secretagogue use in this population.

Hepatic Child-Pugh Classification and Dosing Implications

Because no ipamorelin-specific pharmacokinetic study in liver disease exists, prescribers use the Child-Pugh classification as a proxy scaffold.

| Child-Pugh Class | Features | Suggested Ipamorelin Approach | |---|---|---| | A (5-6 points) | Mild impairment | Standard dose; monitor IGF-1 at 4 weeks | | B (7-9 points) | Moderate impairment | Start at 50% of standard dose; recheck IGF-1 at 3 weeks | | C (10-15 points) | Severe impairment | Avoid; GH-resistance with unbraked GH excess is likely |

These thresholds are clinical consensus, not regulatory guidance, because no manufacturer-sponsored PK trial has been published for this peptide in humans with liver disease. The evidence gap is real, and you should know that before starting.

Sex-Specific Physiology: Why Liver Disease Hits Women Differently

Estrogen, GH Pulsatility, and Hepatic IGF-1

Estrogen status changes GH physiology in women in ways that interact directly with hepatic impairment. Premenopausal women with normal estrogen levels have higher GH pulse frequency than men of the same age, but oral estrogens reduce hepatic IGF-1 production by suppressing GH-receptor signaling. Ho et al. (J Clin Endocrinol Metab, 2006) showed that oral estradiol at standard menopausal doses can suppress IGF-1 by up to 30% compared with transdermal estradiol at equivalent serum estradiol levels. A woman on oral estrogen therapy who also has Child-Pugh B cirrhosis could have markedly suppressed IGF-1 production from two independent mechanisms, making GH feedback even less reliable.

Transdermal or vaginal estrogen does not carry the same IGF-1-suppressing hepatic first-pass effect. If a woman with hepatic impairment also requires hormone therapy, route of administration matters for GH-axis monitoring.

Perimenopause and Post-Menopause

GH secretion declines with age in all people, but the drop in women accelerates around the menopause transition. Veldhuis et al. (J Clin Endocrinol Metab, 2005) quantified that 24-hour GH secretion falls by roughly 14% per decade, and postmenopausal women secrete significantly less GH than age-matched premenopausal women. That means a postmenopausal woman with hepatic impairment starts from a lower GH baseline, and any dose of ipamorelin that achieves a therapeutic response may produce a smaller absolute IGF-1 rise than the same dose in a younger woman, making monitoring thresholds harder to interpret.

Clinically, this argues for measuring both GH (fasting morning) and IGF-1 at baseline before starting ipamorelin in any perimenopausal or postmenopausal woman, and then rechecking at 3-4 weeks regardless of hepatic status.

PCOS

Women with polycystic ovary syndrome often have baseline alterations in the GH-IGF-1 axis. Morales et al. (Fertil Steril, 1996) described relatively preserved GH secretion but elevated free IGF-1 in some PCOS phenotypes due to reduced IGFBP-1 (often suppressed by hyperinsulinemia). If a woman with PCOS also has nonalcoholic fatty liver disease (NAFLD), which is present in approximately 50-70% of women with PCOS, she may have subclinical hepatic dysfunction even with a normal Child-Pugh score. Liver enzymes alone do not capture fibrosis stage; a FibroScan or FIB-4 score is more informative before prescribing.

Standard Dosing Protocol for Women With Normal Hepatic Function

Before covering adjustments, you need to know the baseline to understand what you are adjusting from.

Typical Ipamorelin Dosing Regimens

Standard ipamorelin protocols used in compounding practice run 100-300 mcg per injection, administered subcutaneously 1-3 times daily. The most common starting point in women is 100-150 mcg once daily at bedtime, aligned with the natural nocturnal GH surge. Some protocols add a second injection in the morning in a fasted state.

Dose titration typically happens every 4-6 weeks based on IGF-1 response, aiming for a target IGF-1 in the upper third of the age-adjusted reference range, not above the age-adjusted upper limit of normal.

Body composition changes, if they occur, usually become measurable after 12-16 weeks of consistent use. Sleep quality improvement is often reported earlier, sometimes within 2-4 weeks, though no placebo-controlled trial in women has confirmed this timeline.

Injection Technique and Timing

Subcutaneous injection into the periumbilical abdomen, lateral thigh, or lateral upper arm. Rotate sites. Inject on an empty stomach when possible, because a large insulin spike from a carbohydrate-heavy meal can blunt the GH pulse by 30-40%. Waiting at least 2 hours after eating, or injecting before bed in a fasted state, preserves peak response.

Dosing Adjustments for Hepatic Impairment

This is the section with the most direct clinical value for the primary query, and also the section with the most honest uncertainty.

Child-Pugh A (Mild Impairment)

No formal dose reduction is required based on available data. Standard starting doses apply. You should add IGF-1 and fasting GH to the 4-week monitoring panel that you would order for any new ipamorelin patient. Liver synthetic function is preserved in Child-Pugh A, so the IGF-1 brake on GH is generally intact.

Child-Pugh B (Moderate Impairment)

Start at 50% of the intended dose, typically 50-100 mcg once daily at bedtime. Recheck IGF-1 and liver function at 3 weeks. If IGF-1 remains in the lower third of the age-adjusted reference range and the patient is tolerating the peptide without side effects (fluid retention, joint discomfort, paresthesia), the dose may be titrated up by 25 mcg increments at no faster than every 3 weeks. The slower titration interval, compared with the standard 4-6 weeks, reflects the less predictable GH-IGF-1 feedback loop.

Watch especially for signs of GH excess: ring tightness, morning hand swelling, carpal tunnel symptoms, or unexplained blood glucose rise. These are early clinical signals that GH is accumulating without adequate IGF-1 counter-regulation.

Child-Pugh C (Severe Impairment)

Avoid ipamorelin. The hepatic IGF-1 production capacity is severely compromised in decompensated cirrhosis, and the normal negative feedback on GH is functionally absent. GH accumulation in this setting carries risk of fluid overload, which is particularly dangerous in a population already at risk for ascites and hyponatremia. No clinical benefit data exist to justify this risk.

Nonalcoholic Fatty Liver Disease Without Cirrhosis

NAFLD without significant fibrosis (F0-F1 by FibroScan) generally does not impair IGF-1 production enough to require dose adjustment. Women with F2-F3 fibrosis (significant but not cirrhotic) occupy an intermediate zone. A conservative approach is to start at the lower end of the standard range (100 mcg once daily) and titrate based on IGF-1 response at 4 weeks, rather than applying a formal Child-Pugh reduction.

Monitoring Parameters in Hepatic Impairment

Order these labs before starting and at 3-4 week intervals during the first 12 weeks:

• IGF-1 (age-adjusted reference range)
• Fasting morning serum GH (single point, not definitive but useful for trend)
• ALT, AST, total bilirubin, albumin, INR
• Fasting glucose and insulin (especially in PCOS or perimenopausal women)
• Blood pressure (fluid retention can raise BP before obvious edema appears)

The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults recommends targeting IGF-1 within the age- and sex-adjusted normal range during GH therapy. That same principle applies to secretagogues, though the guideline was written for approved recombinant GH, not peptides.

Pregnancy and Lactation Safety

Ipamorelin is contraindicated in pregnancy. This must be stated clearly, not buried in fine print.

Pregnancy

No human pregnancy safety data exist for ipamorelin. The drug has not been assigned a formal FDA pregnancy category because it was never approved as a finished drug product. Animal reproductive toxicology studies specific to ipamorelin are not publicly available in peer-reviewed literature.

The pharmacological concern is mechanistic. GH-axis activation during organogenesis and fetal development carries theoretical risk. GH signaling participates in placental development, and excess GH-axis stimulation during pregnancy has been associated in animal models with fetal overgrowth and metabolic programming effects, though these data come from recombinant GH studies, not ipamorelin specifically.

ACOG advises that off-label compounded peptides without human pregnancy safety data should be discontinued before conception is attempted or immediately upon confirmed pregnancy.

If you are trying to conceive, ipamorelin should be stopped at least one full menstrual cycle (ideally 4-8 weeks) before attempting pregnancy. Use reliable contraception while on any compounded GH secretagogue. An IUD, implant, or combined oral contraceptive are all appropriate options depending on your other health considerations.

Lactation

Avoid ipamorelin during breastfeeding. Peptide transfer into breast milk has not been studied. The molecular weight of ipamorelin (approximately 711 Da as the free peptide, 827 Da as the acetate salt) is small enough that transfer into milk is theoretically possible, though gastric proteolysis in the infant would likely degrade most of it before absorption. The phrase "likely degraded" is not the same as "safe." Given the unknown infant GH-axis effects and the absence of any pharmacokinetic data in lactating women, the precautionary recommendation is to hold the drug while breastfeeding.

Contraception Requirement

Any woman of reproductive age prescribed ipamorelin by a compounding prescriber should use effective contraception for the duration of therapy, given the lack of human pregnancy safety data. Discuss your contraception plan with your prescriber before your first injection.

Who This Is Right For and Who Should Avoid It

Potentially Appropriate Candidates (Women)

• Postmenopausal women with well-documented adult GH deficiency or age-related somatopause, Child-Pugh A liver function, and a clear monitoring plan
• Perimenopausal women with significant body composition changes and low-normal IGF-1, no hepatic fibrosis, not pregnant or attempting pregnancy
• Women with PCOS and documented GH-axis blunting, with F0-F1 NAFLD at most, who have optimized insulin resistance first
• Women pursuing body composition support after completing cancer treatment (excluding hormone-sensitive cancers), with Child-Pugh A status

Women Who Should Avoid Ipamorelin

• Any woman who is pregnant, planning pregnancy, or breastfeeding
• Child-Pugh B or C hepatic impairment (Child-Pugh B only with significant caution and specialist supervision)
• Active or history of hormone-sensitive cancer (GH and IGF-1 have mitogenic signaling)
• Uncontrolled type 2 diabetes (GH is anti-insulin; secretagogues can worsen glycemic control)
• Acromegaly or pituitary tumor
• Severe renal impairment (peptide clearance data are also absent for this population)

The Evidence Gap: What Has Not Been Studied in Women

Women have been systematically under-represented in peptide pharmacology research. The Raun 1998 trial, which remains the primary evidence base for ipamorelin's selectivity, was conducted in male Wistar rats. There are no published large-scale randomized controlled trials of ipamorelin in women at any life stage, and no pharmacokinetic study has enrolled women with hepatic impairment, examined how menstrual cycle phase affects GH response to ipamorelin, or compared dose requirements across reproductive, perimenopausal, and postmenopausal stages.

What clinicians know about ipamorelin dosing in women with liver disease is extrapolated from:

1. The general GHRP pharmacology literature (mostly male subjects or mixed cohorts)
2. Cirrhosis physiology studies documenting GH resistance (not ipamorelin-specific)
3. Child-Pugh dose-adjustment frameworks developed for small-molecule drugs, applied by analogy to peptides
4. Clinical experience at compounding-prescriber practices, unpublished and unstandardized

The Endocrine Society has called for sex-disaggregated reporting in all endocrine clinical trials as of 2021. Until that standard is applied to GH secretagogue research, dosing recommendations for women, and particularly women with organ impairment, will remain extrapolated rather than evidence-based. Honest prescribing acknowledges this.

Practical Protocol Summary for Prescribers and Patients

A woman asking her prescriber about ipamorelin in the context of hepatic disease should expect these steps before a prescription is written:

1. Full liver function panel plus FIB-4 or FibroScan to stage fibrosis, not just liver enzymes
2. Child-Pugh classification performed explicitly
3. Baseline IGF-1 (age-adjusted) and fasting GH
4. Pregnancy test if premenopausal; contraception plan documented
5. Estrogen route confirmed (transdermal preferred if HRT is co-prescribed)
6. Dose selected per Child-Pugh class using the table above
7. 3-week follow-up IGF-1 and symptom review for Child-Pugh B; 4-week for Child-Pugh A

A Child-Pugh B woman should not receive a standard 200-300 mcg dose on day one. Starting at 100 mcg once daily at bedtime and titrating based on monitored IGF-1 response, rather than symptom report alone, is the safest approach the current evidence supports.